Royalty Pharma partners with J&J on $500M drug development deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
March 30, 2026 7:15 AM EDTNEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
JNJ4804 is a novel coantibody therapy that blocks the complementary interleukin23 (IL23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immunemediated diseases.
We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ-4804, said Pablo Legorreta, Chief... More
